Initial assessment in the management of adult epistaxis: systematic review by Khan, Maha et al.
 1 
Title Page 
 
The initial assessment of adult epistaxis patients: A systematic 
review  
 
Maha Khan1, Katherine Conroy2, Kishan Ubayasiri3, James Constable3, Matthew E 
Smith4, Richard J Williams5, Isla Kuhn6, Mary Smith7, Carl Philpott8 
1. University Department of Otolaryngology, Central Manchester University Hospitals 
2. Department of Otolaryngology, University Hospitals of South Manchester 
3. Queen’s Medical Centre, Nottingham 
4. Department of Otolaryngology, Addenbrooke’s Hospital, Cambridge 
5. Institute of Naval Medicine, Gosport, UK 
6. University of Cambridge School of Clinical Medicine, Cambridge, UK 
7. Exeter Health Library, Peninsula Medical School, Exeter 
8. Norwich Medical School, University of East Anglia, Norwich, UK 
 
Miss M Khan   Specialist Trainee in Otorhinolaryngology, MBChB 
Miss K Conroy  Specialist Trainee in Otorhinolaryngology, MB BChir 
Mr K Ubayasiri  Specialist Trainee in Otorhinolaryngology, MSc, MScIT, BMBS 
Mr J Constable  Core Surgical Trainee, BSc, BMBS  
Mr ME Smith  Specialist Trainee in Otorhinolaryngology, MA, MB BChir 
Mr RJ Williams  Specialist Trainee in Otorhinolaryngology, BMBS, FRCS (ORLHNS) 
I Kuhn   Medical Librarian, MA (Hons), MSc 
M Smith  Medical Librarian, BA, MCLIP 
Prof C Philpott  Professor of Rhinology & Olfactology, Honorary Consultant ENT 
Surgeon & Rhinologist 
 
Corresponding author: 
Maha Khan, 
University Department of Otolaryngology, 
Peter Mount Building, 
Central Manchester University Hospitals, 
Oxford Road, 
Manchester, 
M13 9WL 
Tel. 0161 276 1234 
 
Conflicts of interest: 
None declared 
 
MeSH Key words: 
Epistaxis; Comorbidity; Cardiovascular diseases; Hypertension; Risk Factors; First 
Aid; Therapy 
 
Funding: 
This review was part of an epistaxis management evidence appraisal and guideline 
development process funded by ENTUK. The funding body had no influence over 
content.  
 
 2 
ABSTRACT 
 
Background: The initial assessment of epistaxis patients commonly includes: first aid 
measures; observations; focused history taking; clinical examination and investigations. 
This systematic review aimed to identify evidence to inform us of how the initial 
assessment of these patients should be conducted.  
 
Methods: Systematic review of the literature performed using a standardised 
methodology and search strategy.  
 
Results: Seventeen articles were included. Factors identified were: comorbidity, intrinsic 
patient factors, coagulation screening and ice pack use. Hypertension and anticoagulant 
use are demonstrated to adversely affect outcomes. Coagulation screening is useful in 
patients on anticoagulant medication. Four studies could not be accessed. Retrospective 
methodology and insufficient statistical analysis limit several studies. 
 
Conclusions: Sustained ambulatory hypertension, anticoagulant therapy and posterior 
bleeding may be associated with recurrent epistaxis, and should be recorded. Oral ice 
pack use may decrease severity and can be considered as first aid. Coagulation studies 
are appropriate for patients with history of anticoagulant use or bleeding diatheses. 
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INTRODUCTION 
 
Epistaxis can be a life-threatening emergency and requires appropriate and structured 
initial assessment.  In the absence of national guidance, however, it is currently unclear 
what this initial assessment should entail.  Elements of initial assessment commonly 
include: the instigation of first aid measures; recording of physiological parameters; 
taking a focus history; clinical examination and requesting appropriate investigations.  
Within these elements it is important that any first aid measures undertaken are known 
to be effective either as a treatment of epistaxis or a method of limiting bleed severity.  
Physiological parameters should be used as measure of illness severity, if demonstrated 
to be valid in our patient group.  When taking a focused history, whilst there are many 
established risk factors for epistaxis, it is key to know what factors affect the outcomes 
of epistaxis sufferers so that management can be tailored according.  The clinical 
examination must be appropriate to guide relevant intervention, however, what should 
this examination include?  At times of financial strain, investigations should be rationed 
to those known to affect our management, however, where should the threshold for 
requesting these test be?  
 
Aims 
This article aimed to systematically review the literature to inform a guideline 
generation process tasked with creating national consensus recommendations for the 
hospital management of epistaxis.  This document will include recommendations on an 
evidence-based approach to the initial assessment of epistaxis patients.  For the 
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purposes of the article this management domain was split into two distinct systematic 
reviews with the following research questions: 
 
1. Patient factors affecting outcome:  What patient factors affect the following 
outcomes in hospital treated epistaxis? 
a. Length of hospital stay 
b. Progression to surgery 
c. Rate of transfusion of blood products 
d. Rate of associated morbidity and mortality 
 
2. Initial management: What represents optimum initial management in terms of? 
a. Where should initial assessment and management be conducted? 
b. Who should be undertaking the initial assessment and management? 
c. What first aid measures should be instigated?  
d. What observations should be undertaken within the initial assessment? 
e. What elements represent appropriate patient examination? 
f. What investigations should be performed in all patients? 
g. What investigations should be performed in selected patients? 
 
METHOD 
 
This work forms part of a set of systematic reviews designed to summarise the literature 
prior to the generation of a UK national management guideline for epistaxis. Following 
the generation of this and other systematic reviews, consensus recommendations on 
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the management of epistaxis were generated based on the evidence and expert opinion 
[reference consensus process, submitted to JLO]. The methodology set out below is 
common to this and four other reviews [reference other reviews submitted].  
 
Generation of research questions: The management of epistaxis was divided into nine 
domains through discussion within a trainee project steering committee. The identified 
domains were: patient factors affecting outcome; initial assessment and first aid; 
cautery; dissolvable nasal packs; non-dissolvable nasal packs; management of 
anticoagulation; other haematological factors affecting outcome; surgical management 
and radiological intervention. Clinically relevant research questions were then 
generated via an iterative consensus process for each domain, to encompass all 
elements of the management of epistaxis. Systematic reviews relating to the nine 
domains have been published in five articles, and the research questions can be found 
within the relevant reviews[references]. Two primary authors led the review of each 
domain, working with centralised library and steering committee support. 
 
Types of study included: Preliminary review of the literature suggested there was a 
limited quantity of high-level evidence in many of the domains. As a result, randomised 
controlled trials (RCTs), controlled and uncontrolled longitudinal studies, plus cross-
sectional studies were all accepted for analysis.  Case series, case reports and opinion-
based articles were excluded. Restrictions were not placed on the outcomes used in 
identified studies at the search stage, in order to ensure capture of all relevant studies.  
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Types of participant: Relevant studies were included if they related to patients aged 16 
and above treated for epistaxis within a hospital environment. Studies including 
paediatric cases or bleeding secondary to hereditary haemorrhagic telangiectasia were 
included in the analysis only if these patients formed less than 30% of the total case 
number.  
 
Search restrictions: There were no publication year or publication status restrictions. 
Only English language articles were included.  
 
Electronic searches: Initially two members of the steering committee (MS and RW) 
independently generated core MeSH and non-MeSH key words to identify relevant 
studies relating to epistaxis. These were then discussed to create a core list of key words 
that formed the basis for the individual domain searches. Domain review authors 
independently generated key words specific to each individual research question, and 
these were also discussed to reach an agreed list. The key word lists were submitted 
two librarians (University of Cambridge Medical Library and Exeter Health Library) who 
together used the core and specific key words to design a search strategy for each 
domain systematic review.  
 
The following databases were searched from their inception for published, unpublished 
and ongoing studies: the Cochrane Ear, Nose and Throat Disorders Group Trials Register; 
the Cochrane Library, including the Cochrane Database of Systematic Reviews, DARE, 
and Cochrane Central Register of Controlled Trials; Medline; EMBASE; CINAHL and Web 
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of Science. Full search strategies can be accessed online as supplementary material. 
Additional studies were identified from the reference lists of full-text articles identified 
in searches, and from existing systematic reviews. All searches were performed in 
February 2016.  
 
Validation of search strategy: To ensure the validity of the search strategy domain co-
authors manually identified two articles relevant to each systematic review. The 
librarians used these to test the search strategy for each domain, adjusting the 
strategies if necessary. Finally the domain review authors were issued the search results 
(including abstracts) for all identified papers.  
 
Screening and eligibility assessment of studies: The two domain authors independently 
scrutinised the identified abstracts, and requested full text articles for any studies that 
appeared relevant to either authors. Records were kept of all excluded studies, 
including the reasons for their exclusion. When potentially relevant full-text articles 
could not be obtained through local sources the Defence Medical Services Library 
assisted via inter-library loan, and failing this articles that were still not obtainable were 
excluded from data extraction.  
 
Data extraction and management: Continuing to work independently, the two domain 
authors extracted data from the identified studies into a standardised online form that 
was designed by the steering committee and librarians, and hosted on Google Drive. 
Meta-analysis was not routinely performed unless data were of sufficient quantity and 
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quality to make this relevant.  
 
Assessment of risk of bias: For the purposes of bias assessment studies were divided 
into RCT and non-randomised trials with or without comparator. The assessment of RCT 
risk of bias was performed using the Cochrane Collaboration’s tool for assessing risk of 
bias3. This tool lists seven potential sources of bias that may affect the internal validity 
of a RCT, and each is assigned a risk of bias judgement (low, unclear or high). Non-
randomised trials were assessed using the MINORS criteria4. The score is calculated by 
awarding 0, 1 or 2 pts to multiple criteria (e.g. clearly stated aims) before totalling these 
to achieve a final figure. The MINORS scores is calculated out of a possible 16, or 24 in 
the presence of a comparative group, with higher scores representing a lower risk of 
bias. Authors independently completed relevant bias assessment proformas for each 
included study. 
 
Data synthesis: Following independent data extraction and assessment of bias, the co-
authors for each domain reviewed the extracted information to reach a joint consensus. 
These data were used to populate a data synthesis table to summarise the findings of 
the systematic reviews, with the format standardised across the nine domains. If 
homogeneity permitted a meta-analysis of key outcomes was performed, with narrative 
review otherwise performed.  
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REVIEW 1: PATIENT FACTORS AFFECTING OUTCOME 
 
 
Figure 1: PRISMA diagram for the patient factors review, mapping the number of records identified, included and excluded 
during different review phases 
 
Results  
Figure 1 documents the search and article selection process. Of the fourteen studies 
included, one is a randomised controlled trial.1 Other studies consist of; five prospective 
controlled studies,2-6 two retrospective controlled longitudinal studies,7, 8  five 
retrospective uncontrolled longitudinal studies9-13 and one prospective uncontrolled 
longitudinal study.14 The studies varied significantly in sample size, ranging from 16 to 
16,828. Subjects’ ages ranged from 0 to 98 years (median 41.5 – 81.7 years, mean 34.2 – 
84.3 years).  In terms of sex distribution, 61.4% of participants were male and 38.6% 
female overall. 
Quality of the evidence as assessed by risk of bias was variable, but overall poor to fair 
with a mean MINORS score of 16.293.25 (range 10-20/24) for the controlled non-
RCTs,2-8 and a mean MINORS score of 10.501.38/16 (range 8-12/16) for the 
uncontrolled non-RCTs.9-14 The RCT which compared rebleeding rates between 
inpatients with epistaxis who were mobilised with those who were rested, was biased 
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regarding ambiguous concealment of the alternate rather than random allocation to 
groups, and not all outcomes were reported. Due to the study setting on a busy ward, 
there was the potential for outcomes to be missed and blinding uncovered.1 None of the 
studies stated that a sample size calculation had been performed. 
 
Summary of Evidence 
1a. Comorbidity 
i. Hypertension:  Hypertension appears to be associated with persistent and recurrent 
epistaxis, as demonstrated by six studies (Table 1).2, 5, 7, 8, 12, 13 Terakura et al. compared 
blood pressures in patients with controlled and persistent bleeding following application 
of an intranasal dressing with adrenaline and lignocaine. Both a diagnosis of 
hypertension and elevated systolic blood pressure at presentation were associated with 
ongoing epistaxis.13 Five studies assessed the relationship between hypertension and 
recurrent epistaxis, of which four were controlled2, 5, 7, 8 and one uncontrolled.12 These 
were larger and of a higher quality as compared with the included studies overall (mean 
participants 1124 +/- 861; mean MINORS scores 17/24 a 12/16). Three studies (including 
the uncontrolled study12) demonstrated that recurrent epistaxis was associated with a 
medical history of hypertension. One of these studies, the only prospective study, also 
found that sustained hypertension was a significant predictor of recurrent epistaxis with 
these patients experiencing a mean of five episodes, as compared with one episode in 
patients with non-sustained hypertension.5  
Conversely, two studies found no association between hypertension and recurrent 
epistaxis. Though Beran et al (1986)2 stated no significant difference in blood pressures 
of patients with recurrent epistaxis as compared with the general population, the 
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authors did not report the results which this statement was based on. In addition, the 
definition of hypertension in this study could be considered less reliable, with blood 
pressure measured on a single occasion only. This was then compared with existing data 
from a much larger population sample dataset (23,794 subjects) rather than a direct 
cohort. Ando et al. (2014) found no significant difference in past medical history of 
hypertension between patients with single and recurrent episodes of epistaxis. 
However, there were large differences between group sizes as the single incident group 
was 8.3 times larger than the recurrent bleeding group, and follow-up period and 
attrition were not clearly stated.8 
 
Atherosclerosis associated with cardiovascular disease has been proposed as a risk 
factor in epistaxis.20 Cardiovascular risk factors including sustained ambulatory 
hypertension, anticoagulant and antiplatelet use appear to be associated with 
persistent, recurrent or heavier epistaxis.2-9, 12, 13 This is of particular relevance as 
treating an ageing population with increasing comorbidity is associated with increasing 
health and social care responsibility and cost.21 However, evidence regarding the 
influence of demographic features and other comorbidities on the outcome in patients 
with epistaxis is limited in both quality and number of studies.  
 
 12 
Study details Groups HTN definition Outcome measure BP (mmHg) Comment P value 
Terakura et al. 
Retrospective 
longitudinal 
uncontrolled 
History of HTN 72/133; 
persistent epistaxis 26/72 
(29%); no history of HTN 
61/133; persistent epistaxis 
8/61 (13%) 
History of HTN 
 
 
Elevated SBP at 
presentation 
Persistent bleeding after 
removal of intranasal dressing 
with adrenaline and 
lignocaine for 30 minutes 
NR 
 
 
Persistent bleeding group 
mean 181.3+26.9 
No bleeding group mean 
156.6+26.1 
 <0.002 
 
 
 
<0.001 
Abrich et al. 
Retrospective 
longitudinal 
controlled 
HTN in recurrent epistaxis 
group – 310/461 (67.2%) 
HTN in single episode group – 
608/912 (66.7%) 
History of HTN 
 
Recurrent epistaxis – at least 
2 episodes separated by 
minimum of 3 months within 
a 36-month period (controls – 
1 episode only) 
NR  0.04 
Herkner et al. 
Prospective 
controlled 
Epistaxis group – 213 
 
Recurrent epistaxis subgroups 
– NS 
 
Control group - 213 
Elevated BP on admission 
– SBP >140 or DBP >90 
 
Sustained arterial HTN  
24-hour mean SBP > 
130mmHg, or DBP > 
85mmHg or both, OR 
receiving long-term anti 
HTN treatment 
 
Recurrent epistaxis Epistaxis group – median 
SBP 161 (IQR 139-180); 
DBP 84 (IQR 70-96) 
 
Control group – median 
SBP 144 (IQR 130-157); 
DBP 75 (IQR 64-81) 
Recurrent epistaxis group 
NS 
Sustained 
arterial HTN 
subgroup - 
mean of 5 
episodes  
 
Non-sustained 
arterial HTN– 
mean of 1 
episode 
0.004 
Beran et al. 
Prospective 
controlled 
Epistaxis – 121 patients; HTN 
15/121 
Control group – 121  
BP population sample 23,794 
Elevated BP on a single 
occasion 
Recurrent epistaxis >3 
episodes per year for 2 
consecutive years 
NS (represented 
graphically within the 
paper) 
 NR 
Ando et al. 
Retrospective 
longitudinal 
controlled 
Single episode epistaxis – 267; 
HTN in 51.7% 
Recurrent epistaxis – 32; 
HTN in 50% 
Established diagnosis of 
HTN 
Recurrent epistaxis after 
treatment of first episode 
NR Single episode 
group 8.3 times 
larger than 
recurrent group 
NR 
Purkey et al. 
Retrospective 
longitudinal 
uncontrolled 
2405 patients with epistaxis – 
41.37% (995) HTN 
3666 cases of epistaxis – 
39.47% (1447) HTN 
ICD-9 coded HTN (401.X) Recurrent epistaxis - number 
of presentations per patient 
NR 1.45 episodes 
per patient with 
HTN. HTN was 
considered 
significant 
predictor for 
recurrent 
epistaxis 
<0.0001 
Table 1 – Hypertension and recurrent epistaxis - Abbreviations: HTN – hypertension, BP – blood pressure, SBP – systolic blood pressure, DBP – diastolic blood pressure; NR – Not reported 
  
ii. Anticoagulation:  Six studies (four controlled 3, 4, 6, 7 and two uncontrolled studies9, 14) 
suggest that anticoagulant use adversely affects the outcome in epistaxis, causing 
recurrent and heavier bleeding and an increased incidence of blood transfusion. The 
quality of these studies is similar to that of the studies overall (mean MINORS scores 
16/24 and 11/16). Both the largest9 and some of the smallest studies4, 14 are 
represented (range 40-16828, mean 3105 ±6742). 
More frequent and heavier bleeding is associated with anticoagulant use in three 
studies (Table 1).3, 7, 14 The anticoagulant medications used varied between the studies 
(Table 2). In one study recurrent bleeding was higher in individuals using warfarin, or a 
combination of warfarin and aspirin. Recurrent bleeding rates were not higher in those 
using other individual or combination anticoagulants, though sample sizes were too 
small to draw reliable conclusions.7 Two prospective studies evaluated the severity of 
bleeding3, 14 A controlled study demonstrated a higher incidence of blood transfusion 
amongst admitted epistaxis patients taking dabigatran or acenocoumarol as compared 
with those taking no anticoagulant.3 One uncontrolled study found that patients who 
had taken any medication associated with increased bleeding risk (anticoagulant or non-
anticoagulant) were more likely to present with heavier bleeding as compared with 
patients not taking these medications.14 
 
Three prospective controlled studies found that anticoagulant use was associated with a 
longer admission.3, 4, 6 This was significant in two of these studies, both of which 
attributed this finding to the routine inpatient management of anticoagulation, 
alongside social and medical conditions.4, 6 Contemporary practice favours outpatient 
 anticoagulation management and these results may now be of limited relevance. In the 
third of these studies, patients with persistent bleeding following removal of nasal 
packing required a period of observation which contributed to increased length of stay 
in patients taking dabigatran (5.9±1.9 days) and acenocoumarol (4.3±1.1 days) as 
compared with patients not taking any anticoagulant medication (3.6±2.4 days) but this 
did not achieve significance.3 
 
In a multicentre retrospective longitudinal study, the largest included in this review, 
Goljo et al. (2015) found that the 20.8% of 16828 patients admitted with epistaxis who 
were taking anticoagulant medication had a significantly lower cost and length of stay 
(LOS) following multiple linear regression analysis, as compared with the sample in 
general. Amongst the studied population the most common comorbidities were 
cardiovascular disease (78.5%), type II diabetes (25.4%) and anticoagulant use (20.8%). 
Factors associated with increased cost and length of stay were an increasing number of 
chronic comorbidities, necessity for operative intervention, Asian/Pacific islander (cost) 
or black race (LOS), top income quartile (cost), private insurance (cost), Medicaid 
insurance (LOS), teaching hospital admission (cost) and certain geographical features. 
Subgroup analyses of patients using anticoagulant medication were not performed to 
determine whether any of these confounding factors contributed to the lower cost and 
length of stay amongst these patients. Furthermore, this study represented patients in 
the United States where practices and pricing of care may differ from those in the 
United Kingdom.9 
 
 NICE key therapeutic topic information indicates the use of Novel Oral Anticoagulants 
(NOACs) in the prevention of a number of serious and common medical conditions, 
including stroke, some adverse outcomes associated with acute coronary syndromes 
and in the treatment and secondary prevention of venous thromboembolism and its 
complications.22 The MHRA issued a warning of risk of serious haemorrhage against 
three of these drugs which were licensed at the time (apixaban, rivaroxaban, 
dabigatran),23 however the evidence represented in this review concerns primarily the 
oral anticoagulant warfarin, with only one study evaluating adverse outcomes in the 
epistaxis patient using NOACs.3 
 
Study details Adverse 
outcome 
measure 
Outcome 
definition 
Medication 
groups 
Adverse 
outcome 
P value 
Abrich et al. 
Retrospective 
longitudinal 
controlled – 
17/24 
Recurrent 
bleeding 
At least 2 
episodes 
requiring 
medical care, 
separated by 
a minimum of 
3 months 
within a 36-
month period 
Warfarin 
127/461 cases 
179/912 controls 
 
Warfarin & aspirin 
51/461 cases 
78/912 controls 
 
27.0% cases 
vs 19.6% 
controls 
 
 
11.1% cases 
vs 7.7% 
controls 
0.001 
 
 
 
 
0.01 
Callejo et al. 
Prospective 
controlled –  
10/24 
Severity of 
bleeding 
Blood 
transfusion 
Dabigatran  
5 patients 
 
Acenocoumarol 
17 patients 
 
No anticoagulant 
18 patients 
4/5; 80% 
 
 
10/17; 59% 
 
 
7/18; 38% 
<0.01 
Klossek et al. 
Prospective 
longitudinal 
uncontrolled – 
12/16 
Severity of 
bleeding 
 
 
 
 
>250ml blood 
loss 
Medication with 
associated bleeding 
risk* 
 
No medication with 
associated bleeding 
risk 
67% 
 
 
 
33% 
0.02 
Table 2 – Anticoagulation and adverse outcomes - *antiplatelet medication, non-steroidal anti-inflammatory drugs, salicylate 
derivatives, vitamin K antagonists, beta-lactams, antidepressants, long-term corticosteroid therapy 
 
 
 iii. Rhinological Comorbidity: Nasal mucosal congestion in rhinitis and rhinosinusitis has 
been implicated in the aetiology of epistaxis, but there is insufficient evidence to 
support an association between this and patient outcomes. Only one controlled study 
considered this relationship. When rhinological factors associated with recurrent 
epistaxis as compared with single episode bleeding were reviewed, no significant 
differences in the incidence of rhinitis (2.6% case vs 1.3% control), sinusitis (1.1% vs 
1.3%) or upper respiratory tract infection (1.5% vs 1.5%) were found.7 
 
iv. Other Comorbidity: The relationship between other comorbidities and patient 
outcomes in epistaxis was considered in one controlled7 and one uncontrolled 
retrospective study.9 Abrich et al. (2014)7 found recurrent epistaxis was associated with 
congestive heart failure (p<0.001) and diabetes (p=0.04). In a longitudinal uncontrolled 
study of 16,828 patients by Goljo et al. (2015), an increasing number of comorbidities 
was associated with a longer hospital stay in patients admitted with epistaxis due to the 
management of co-existing medical conditions (p<0.001).9 This study examined patients 
admitted to multiple centres in the United States where practices may differ from those 
in the United Kingdom. 
 
1b. Intrinsic risk factors 
i. Bleeding site: Two retrospective longitudinal studies l studies looked at the 
relationship between anterior and posterior bleeding site and patient outcome. Both 
studies demonstrated that posterior site epistaxis is more frequently associated with 
recurrent bleeding.8, 11 In one of these studies, Ando et al. (2014) found anterior 
 bleeding was significantly associated with non-recurrent epistaxis (191/198 patients). 
Each non-anterior bleeding site was analysed independently rather than as posterior 
epistaxis in general, and failure to identify the bleeding point (14/267 single episode vs 
17/32 recurrent, p=0.000) was also associated with recurrent epistaxis. Bleeding from 
either the olfactory cleft, middle or inferior meati, or other non-anterior site did not 
achieve significance, though numbers in these subgroups are much smaller than the 
anterior bleeding group.8  
 
ii. Severity of bleeding: Patients with more severe bleeding appear more likely to 
undergo surgical intervention.  In a single small retrospective longitudinal study the 
severity of bleeding in patients who underwent sphenopalatine artery (SPA) ligation 
(n=27) was compared with those who did not (n=71). Four measures of severity were 
significant predictors for surgery:  
a. persistent uncontrolled epistaxis despite anterior and posterior packing 
(21/27 vs 1/71, p<0.0001) 
b.  three or more episodes of recurrent bleeding (17/27 vs 0/71, p<0.0001) 
c. blood transfusion or haemoglobin decrease of greater than 4g/dL (9/27 
vs 4/71, p<0.0001,) 
d. three admissions for ipsilateral bleeding in three months (4/27 vs 0/71, 
p<0.0001).10 
 
 iii. Demographic and social history: Patient age was found not to be associated with 
recurrent bleeding in one retrospective controlled study7. Age also appears to have no 
relationship with continued bleeding after pack removal.13 
 
iv. Alcohol intake: Excess alcohol consumption and alcohol-induced platelet dysfunction 
has been implicated as a risk factor for epistaxis.15, 16 Evidence relating history of alcohol 
intake to patient outcome in epistaxis was very limited. Looking at US admission data, 
Goljo et al. (2015) found that a history of alcohol abuse in epistaxis patients (5.8%; 
972/16828) was associated with a significantly increased length of stay (p=0.004).9 In a 
retrospective longitudinal controlled trial, Abrich et al found no difference in alcohol 
consumption between 426 patients with recurrent epistaxis and 912 matched controls.7 
Though the latter study also compared independent history of portal hypertension and 
gastrointestinal bleeding between the two groups (neither was significant), neither 
study considered the influence of any hepatic impairment nor complications of alcohol 
abuse on the patient outcome. 
 
1c. Patient Mobilisation 
It does not appear that patient mobilisation during the hospital stay has any effect on 
rebleeding rate. The only included RCT found no significant difference between 
inpatients who were mobilised (21/50) and those confined to bed rest (24/50).1 The 
mean age for the adult patient with epistaxis in the presented data was 65.4, meaning 
many patients are above the age of 60 and therefore at higher risk for the development 
of venous thromboembolism24. Patient mobility plays a key role in the prevention of 
 venous thromboembolism24 and on the basis of limited evidence it would appear 
sensible for  the epistaxis patient to mobilise lightly without increased risk of 
rebleeding.1 
 
Limitations 
The primary limitations were low quality evidence and poor study design as 
demonstrated by applying the MINORS criteria to assess methodological quality of non-
randomised surgical studies. There were a lack of prospective controlled trials, with only 
one RCT could be included1, and six of the fourteen included studies uncontrolled9-14. 
The remaining seven studies were retrospective in their methodology.7, 9-13 Within and 
between studies there were fundamental differences in baseline demographic 
characteristics and comorbidities between the participant groups compared. 
Furthermore, heterogeneity of study design and poorly defined outcomes meant that 
meta-analysis was not possible.  Of particular note, definitions of hypertension were 
inconsistent 2, 5, 7, 8, 12, 13 and variation was seen among the anticoagulant medications 
used in different studies.3, 4, 6, 7, 9  
 
  
 REVIEW 1: INITIAL MANAGEMENT 
 
 
Figure 2: PRISMA diagram – First Aid 
 
 
Figure 3: PRISMA diagram – Initial Assessment 
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 Results 
Figures 2 and 3 document the search and article selection process for the First aid and 
initial assessment parts of this review. Three stiudies were included of which none were 
RCTs. Two were prospective controlled studies regarding to ‘First Aid’ measures, with a 
total number of 72 participants (16-56). Both papers assessed the effect of topical ice 
packs on nasal mucosal blood flow in healthy volunteers as measured by laser Doppler 
flowmetry at Kiesselbach’s plexus17 or the inferior turbinate18. The studies were of a fair 
quality overall, both demonstrating a MINORS score of 17/24, with robust, simple and 
reproducible methodology. A single retrospective uncontrolled longitudinal study 
relevant to ‘Initial Assessment’ of the patient with epistaxis was of fair quality (MINORS 
8/16) and reviewed the use of coagulation studies in 183 cases.19 
 
Summary of Evidence 
2a. First Aid 
Various first aid measures have been adopted for the treatment of epistaxis despite a 
lack of evidence. The only first aid measure described in included studies was the use of 
an ice pack. Application of an intraoral ice pack has the potential to decrease nasal 
blood flow, and this may in turn decrease the severity of epistaxis, although this has yet 
to be demonstrated. In one study intraoral ice significantly reduced the nasal blood flow 
at the inferior turbinate (23%) as compared with a control pack (-5%, p<0.05)18. An ice 
pack placed on the forehead failed to achieve a significance reduction in nasal blood 
flow.17, 18 In one of these studies, the standard deviations in mean blood flow following 
forehead application in both participant groups were very large which suggested 
 heterogeneity amongst individual results within a small study (1368.8±927.9 before vs. 
1130.5±792.2 after, p=0.11).17] 
 
2b. Initial assessment: 
Coagulation screening is seen to be of benefit only in epistaxis patients on anticoagulant 
therapy or with a history of bleeding diatheses, as results are otherwise likely to be 
normal and not add to the management process.  An abnormal result is of clinical value 
and can guide overall management. In a retrospective longitudinal study over one year, 
Thaha et al. (1999) found that all 10/121 (8.3%) of patients with epistaxis who had 
abnormal coagulation studies were using the oral anticoagulant warfarin, and no other 
coagulation abnormalities were identified in the studied population.19 This is the only 
included study the relevant to the role of coagulation screening. 
 
A single uncontrolled retrospective study set in a large Scottish teaching hospital is 
included in the ‘initial assessment’ section of the review. Of all patients with epistaxis 
who had coagulation studies performed only 8.3% were abnormal, and furthermore 
these were exclusive to patients using the oral anticoagulant warfarin.19 Though at the 
time of this review there is an absence of data representing the frequency and cost of 
coagulation screening in epistaxis patients in the United Kingdom, considerable cost 
savings could likely be achieved with more judicious use of the tests.  
 
Limitations 
 Despite a potentially extensive theme, only two topics were represented within the First 
Aid and Initial Assessment review.17-19 due to a lack of published studies. The primary 
limitations with identified studies were low quality evidence and study design. The 
controlled studies did not declare adequate power17, 18. Both controlled studies within 
the ‘first aid’ section studied the effect of ice pack application on nasal blood flow in 
young, healthy volunteers with a median age of 31 years between the studies.17, 18 This 
healthy, young group is not representative of that seen clinically, with a median age of 
patients within the ‘patient factors’ review of 66 years1, 3-11, 13, 14 and comorbidities were 
present in 58.6% of these patients overall (where stated).1, 3, 6-9, 11, 14 
 
Conclusions 
Cardiovascular risk factors, particularly sustained ambulatory hypertension, and 
anticoagulant or antiplatelet use appear to be associated with persistent, recurrent or 
heavier epistaxis. When assessing a patient with epistaxis a history of cardiovascular 
disease and medications should be sought, and where possible, the site of bleeding 
should be identified and recorded, as posterior or unidentified site bleeding can be 
associated with recurrent or recalcitrant epistaxis.  
 
Application of an intraoral ice pack is a simple first aid measure which has the potential 
to decrease the severity of bleeding and should be considered from the onset of 
epistaxis to point of hospital care. Evidence supporting the efficacy of other topical ice 
packs is insufficient. There is limited evidence to suggest that coagulation studies should 
 be reserved for patients taking anticoagulant medication or with a history of bleeding 
diatheses, as they do not add to the management process in other individuals.  
 
In order for robust recommendations to be made, based on the findings of this review 
future adequately powered randomised controlled studies should address effective 
methods of first aid, initial assessment and investigation protocols, and how to best 
manage comorbidities in patients with epistaxis via a multidisciplinary approach. 
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